相关实验视频

Updated: Jul 1, 2025

OP-IVM: Combining In vitro Maturation after Oocyte Retrieval with Gynecological Surgery

OP-IVM: Combining In vitro Maturation after Oocyte Retrieval with Gynecological Surgery

Published on: May 9, 2021

在试管婴儿周期中,慢性子宫内膜炎妇女的孕期准备

Alla V Boychuk¹, Natalia V Kotsabyn², Julia B Yakymchuk¹

¹TERNOPIL NATIONAL MEDICAL UNIVERSITY NAMED AFTER I. YA. GORBACHEVSKY, TERNOPIL, UKRAINE.

Wiadomosci lekarskie (Warsaw, Poland : 1960)

|March 3, 2024

概括

富血小板血 (PRP) 注射改善了慢性子宫内膜炎妇女的活产率. 这种治疗增强了子宫内膜的准备,减少了妊娠损失,并增加了生育成功率.

科学领域:

生殖医学生殖医学
妇科妇科妇科妇科
不孕症治疗不孕症治疗

背景情况:

慢性子宫内膜炎 (CE) 是导致流产的重要原因,特别是在体外受精 (IVF) 后.
有效的孕前准备对于管理与CE相关的不孕症至关重要.

研究的目的:

为了改善慢性子宫内膜炎妇女的孕前准备.
通过考虑子宫内膜状况,开发个性化的方法来克服不孕症.

主要方法:

一项涉及90名患有慢性子宫内膜炎和解剖学正常子宫的女性 (年龄28-38岁) 的研究.
第一组 (n=45) 接受了CE的常规治疗.
第二组 (n=45) 通过自主血小板丰富血 (PRP) 的子宫内膜注射接受孕前准备.

主要成果:

生物化学怀孕率在I组为44.4%,在II组为62.2%.
在一年内恢复生育能力在PRP组 (51.1%) 比传统组 (40.0%) 更高.
活产率在II组 (42.2%) 与I组 (20.0%) 相比显著更高,增加了两倍.
与传统组 (17.8%) 相比,PRP组的早期怀孕损失减少了一半 (8.9%).

结论:

在患有慢性子宫内膜炎的患者中,子宫内膜下PRP注射是准备子宫内膜进行胚胎移植的有效方法.
这种方法可以显著增加活产率,并减少患有CE的妇女的怀孕流产.

关键词:

CD 138 CD 138 是一个很好的 CD.慢性子宫内膜炎慢性子宫内膜炎富有血小板的等离子体流产流产流产流产

更多相关视频

Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives

Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives

Published on: September 16, 2021

Laparoscopic Oocyte Retrieval and Cryopreservation during Vaginoplasty for Treatment of Mayer-Rokitansky-Kuster-Hauser Syndrome

Laparoscopic Oocyte Retrieval and Cryopreservation during Vaginoplasty for Treatment of Mayer-Rokitansky-Kuster-Hauser Syndrome

Published on: May 10, 2022

相关概念视频

In Vitro Fertilization

In Vitro Fertilization

In vitro fertilization (IVF) is a form of assisted reproductive technology where an egg is fertilized with sperm in a controlled laboratory environment before transferring the resulting embryo into the uterus. This process is designed to help individuals and couples experiencing difficulties conceiving.
The IVF process begins with ovarian stimulation, during which reproductive endocrinologists prescribe hormonal medications to stimulate the ovaries to produce multiple eggs instead of the single...

Meiosis II

Meiosis II

Meiosis II is the second and final stage of meiosis. It relies on the haploid cells produced during meiosis I, each of which contain only 23 chromosomes—one from each homologous initial pair. Importantly, each chromosome in these cells is composed of two joined copies, and when these cells enter meiosis II, the goal is to separate such sister chromatids using the same microtubule-based network employed in other division processes. The result of meiosis II is two haploid cells, each...

Infertility in Females

Infertility in Females

Female infertility is defined as the inability to conceive after a year of regular, unprotected intercourse and affects about 10–15% of couples worldwide. The primary cause of female infertility is ovulatory disorders, which hinder the release of eggs. These disorders can be classified as hypothalamic amenorrhea, polycystic ovarian syndrome (PCOS), premature ovarian failure, and hyperprolactinemic anovulation disorders.
Endometriosis, a condition characterized by abnormal growth of...

Oogenesis

Oogenesis

In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...